Safety and Efficacy Study of Autologous bone marrow stem cell transplantation for the treatment of Diabetic Neuropathy

Safety and Efficacy Study of Autologous bone marrow stem cell transplantation for the treatment of Diabetic Neuropathy: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002570

Enrollment

Unknown

Registered

2012-10-14

Start date

2010-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Neuropathy

Interventions

Group A:Stem cell and drug therpy

Group B:Drug therapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed type 2 diabetes; 2. Patients with distal symmetrical diabetic neuropathy of the legs; 3. Gender is not limited; 4. Aged 18-80 years old; 5. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Neuropathy of other origin; 2. Abnormal liver function tests; Seropositivity for HIV,HBVand HCV; History of myocardial infarction or unstable angina in the previous 3 months; History of malignancy; Active infections; Serious mental conditions.

Design outcomes

Primary

Measure	Time frame
nerve conduction velocity;quantitative sensory test;	—

Countries

China

Contacts

Public ContactShi Zhao

zhaoshiwuhan@126.com+86 13707172291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026